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Qingkailing(QKL)injectionwasafamoustraditionalChinesepatentmedicine,whichwasextensivelyusedtotreattheacutestages
of cerebrovascular disease. The aim of this study was to assess the quantity, quality and overall strength of the evidence on QKL
in the treatment of acute ischemic stroke. Methods. An extensive search was performed within MEDLINE, Cochrane, CNKI, Vip
and Wan-Fang up to November 2011. Randomized controlled trails (RCTs) on QKL for treatment of acute stroke were collected,
irrespective of languages. Study selection, data extraction, quality assessment, and data analyses were conducted according to the
Cochranestandards,andRevMan5wasusedfordataanalysis.Results.7RCTs(545patients)wereincludedandthemethodological
quality was evaluated as generally low. The pooled results showed that QKL combined with conventional treatment was more
eﬀective in eﬀect rate, and the score of MESSS and TNF-α level compared with conventional treatment alone, but there was no
signiﬁcant diﬀerence in mortality of two groups. Only one trial reported routine life status. There were four trials reported adverse
events,andnoobviousadverseeventoccurredinthreetrialswhileonereportedadverseeventsdescribedaseruptionanddizziness.
1.Introduction
Stroke is a major cause of death and disability in the world
and the most important strategy for treatment of ischemic
stroke is prevention and eﬀective therapy. In China, acu-
puncture and traditional Chinese medicine (TCM) have
been used to treat stroke patent medicine or a history over
2000 years. In recent decades, patent medicines of TCM
were widely and regularly used in stroke patients in either
Western medicine hospitals or traditional Chinese medicine
hospitals. However, few studies have been published in
English reporting the eﬀectiveness and safety of many com-
monly used TCM [1, 2]. Currently, there is yet no routine
eﬀective, generally accepted, speciﬁc treatment for ischemic
stroke, except for thrombolytic treatment for highly selected
patients.Therefore,conﬁrmationoftheeﬀectivenessofTCM
c o u l dh a v eag r e a ti m p a c to ns t r o k em a n a g e m e n ti nt h e
world.
Qingkailing (QKL) injection was originally prepared by
the Beijing University of Chinese Medicine in the 1970s, by
modifying a traditional Chinese medicine, Angongniuhuang
pills, composed of Radix Isatidis, Flos Lonicerae, Concha
Margaritifera Usta, baicalin, Fructus gardeniae, cholic acid,
hyodeoxycholic acid, and Cornu Bubali [3]. It has been
extensively used to treat the acute stages of cerebrovascular
disease and has performed excellently in improving neuro-
logical function [4]. Animal experiments have shown that
QKL injection can promote endothelial nitric oxide syn-
thase expression, reduce calcium overload, regulate matrix
metalloproteinase-9 expression, and inhibit inﬂammation
in a murine model of cerebral ischemia/reperfusion [5–8].
Several clinical studies reported the eﬀectiveness ranging
from case reports and randomized clinical trials, but the
evidence for its eﬀect was not clear.
The aim of this study was to assess the quantity, quality
and overall strength of the evidence on QKL in the treatment
of acute ischemic stroke.
2. Methods
2.1. Database and Search Strategies. The electronic databases
of MEDLINE (1982–2011), Cochrane Controlled Trials2 Evidence-Based Complementary and Alternative Medicine
Register ((Issue 10, 2011)), CNKI database (1974–2011), Vip
database (1989–2011), and Wan-Fang database (1998–2011)
were searched by using a combination of MESH subject
headings of “Qingkailing” and “Stroke” or “cerebral infarc-
tion” without language limitation. Reference lists from trials
selected by electronic searching and conference compilations
were hand searched. All of those searches ended before
November 2011.
2.2. Inclusion Criteria. Deﬁnite or possible randomized con-
trolled trials (RCTs) were included. RCTs combined QKL
injection with conventional treatment with the conventional
treatment alone, and QKL injection plus conventional treat-
ment compared with a western medicine plus conventional
treatment were included. While the trials with other TCM
used either in QKL or control groups were excluded. There
were no restrictions on population characteristics, language,
and publication type.
Trials that included patients of any age or sex with acute
ischemic stroke were eligible. Ischemic stroke was deﬁned
if the patients met the World Health Organization or the
similar Chinese National criteria (demanding a CT/MRI
scan as conﬁrmation) of stroke, and hemorrhagic stroke was
excluded. Possible ischemic stroke in which CT/MRI were
not performed was also to be included.
T h ep r i m a r yo u t c o m em e a s u r e sw e r ed e a t ha n de ﬀect
rate (which was based on the neurological deﬁcit improve-
ment),andadverseevents.Thesecondaryoutcomemeasures
were neurological deﬁcit scoring, infarction volume of CT,
inﬂammation factors, and quality of life.
2.3. Data Extraction and Quality Assessment. The data was
entered into an electronic database by the two reviewers
(F. F. Cheng and X. Q. Wang) independently, in the case
where the two entries did not match, and a third person (Y.
Lu) may be involved for veriﬁcation. Quality assessment of
included randomized controlled trials: sequence generation,
allocation concealment, blinding of participants personnel
and outcome assessors, incomplete outcome data, selective
outcome reporting, and other sources of bias [9].
2.4. Data Synthesis. The statistical package (RevMan 5) was
used for data analyses, which was provided by the Cochrane
Collaboration. Dichotomous data were presented as risk
ratio (RR) and continuous outcomes as mean diﬀerence
(MD), both with 95% conﬁdence interval (CI). Heterogene-
ity between trials results was tested, and heterogeneity was
presented as signiﬁcant when I2 is over 50% or P<0.1.
Random eﬀect model was used for the meta-analysis if there
was signiﬁcant heterogeneity and ﬁxed eﬀectmodel was used
when the heterogeneity was not signiﬁcant [9]. Publication
bias was explored via a funnel-plot analysis.
3. Result
3.1. Description of Included Trials. After primary search of 5
databases, 254 trials were screened out from electronic and
manual searches (Figure 1), and the majority were excluded
due to being found from more than one database or obvious
ineligibility which including irrelevant titles and abstract. 6
trials were excluded because of duplicated publication, 62
trials were excluded due to the animal studies, the rest 41
trials were noncontrolled clinical trials including case report,
case series, or review. 145 full text papers were retrieved
and 138 trials were excluded based on the inclusion criteria.
The most frequent reasons for exclusion were other types
of intervention examined (78), either no proper outcomes
reported (29), or not a randomized trial (24), while 7 RCTs
including cerebral hemorrhage were excluded. In the end, 7
RCTs (545 participants) [10–16] were reviewed. All studies
were published in Chinese. The bibliographic details of these
trials are given in Table 1.
The age of patients in the included studies ranged from
33 to 78 years old. All trials included more males (60%
to 70%) than females. All included trials applied standard
medicine diagnostic criteria for ischemia stroke, and all of
them reported the need for all patients to have had CT/MRI
scanning to conﬁrm the diagnosis. Only QKL injection was
studied in these included trials. The dose range of QKL
injection was from 30mL to 80mL and dose route was intra-
venous injection in all included studies. Most of included
trialsweredesignedtocomparedQKLinjectionplusconven-
tional treatment with the conventional treatment alone,
the later including basic therapy, and urokinase, and only
one trail [10] compared QKL injection plus conventional
treatment with nimodipine plus conventional treatment
(Table 1). None of the trials was randomized, double-blind,
placebo controlled. The timing of the start of treatment after
stroke onset was within 72 hours, and the total duration of
treatment varied from 7 to 20 days.
All the including trials reported the eﬀect rate, but
only two mentioned the death rate. Only one trial [11]
had undergone assessment of patients’ routine living ability
after treatment. Three trials [11–13] reported neurological
deﬁcit, using the Modiﬁed Edinburgh-Scandinavian Stroke
Scale (MESSS), which was recommended at the Second
and revised at the Fourth National Cerebrovascular Diseases
Conference in China. And one trial [12] measured infarction
volume of CT. Tan et al. [10]a n dW ue ta l .[ 14]r e p o r t e d
inﬂammation factor in blood serum, both including TNF-α
and IL-6. Yang et al. [12] reported the eﬀect of QKL injection
in treating coma induced by stroke.
3.2. Methodological Quality of Included Trials. The method-
ological quality of most included trials was generally “poor.”
The sample size of including trials varied from 40 to
150 patients. None of the 26 trials reported sample size
calculation. None of the trials was properly randomized,
double blinded, placebo controlled, and no trials employed
a blinding procedure, yet only one trial reported the method
of randomization (random number table) [10]. None of
the trials had grade A level of adequate concealment of
randomization. None of the trials reported the number of
patientsthatwerelosttofollowupandwhethertheyhadused
intention-to-treat analysis (Table 2).Evidence-Based Complementary and Alternative Medicine 3
Title abstract
CNKI  Vip  PUBMED  Cochrane library  CBM
Total 
Full text
RCT included
138 studies excluded based on 
the inclusion criteria
N = 128 N = 89 N = 4 N = 0 N = 33
N = 254
N = 145
N = 7
Repetitions n = 60, animal
study n = 22
Figure 1: Study selection process.
Table 1: Characteristics and methodological quality of included studies.
Study ID Sample Time of
onset CT/MRI Intervention in
control group QKL injection dose/day Course Followup
(month) Death Adverse eﬀect
Liang 2000 [15]8 0<72h Yes Conventional
treatment 30mL 14d 1 No Unclear
Tan et al. 2003
[10] 65 <72h Yes Conventional
treatment 40mL 14d No 2/2 2 eruption and 1
dizziness
Wu et al. 2007
[14] 88 <72h Yes Conventional
treatment
1200mg (freeze-drying
agent, roughly
equivalent to 60mL)
14d No No Unclear
Yan and Li 2010
[13] 150 <6h Y es
Urokinase +
conventional
treatment
40mL 7d No No No
Yang et al. 2003
[12] 58 <72h Yes Conventional
treatment 80mL 20d No No No
Zeng and Feng
2003 [11] 64 <24h Yes Conventional
treatment 60mL 20d No No Unclear
Yu and Liao 1999
[16] 40 <72h Yes Conventional
treatment 50mL 14d 1 1/7 No
Conventional medicine treatment includes mannital, dextran, nimodipine, aspirin, and so on.
3.3. Eﬀect of the Interventions
3.3.1. Primary Outcomes
Eﬀect Rate. All the seven trials reported clinical eﬀect rate
to evaluate the outcome, which was based on the reduction
of neurological deﬁcit scoring [18]. Four trails [11–14] used
the percentage of MESSS scores reduced rate to measure
the outcome: cure (MESSS scores reduced rate from 91 to
100%), signiﬁcantly eﬀective (MESSS scores reduced rate
more from 46 to 90%), eﬀective (MESSS scores reduced rate
from 18 to 46%), and ineﬀective (MESSS scores reduced
rate less than 18%). Other three studies [10, 15, 16] used
similar evaluation standards at the study time. We put these
two diﬀerent kinds of measurements together to evaluate the
general eﬀectiveness. Total eﬀective rate is the combination
of cure, signiﬁcant eﬀective and eﬀective rate. The meta-
analysis showed signiﬁcant diﬀerence between groups of
QKLinjectionplusconventionaltreatmentandconventional
treatment alone on total eﬀective rate (RR: 1.12 [1.04, 1.19];
P<0.01) (Figure 2).
Death. Two trials [10, 16] out of seven reported death. Tan
et al. [10] assessed death at the end of 2-week therapeutic
course, and Yu and Liao [16]r e p o rt e di t1m o n t ha f t e rs t r o k e
onset. Total number of death was 12 out of 105 patients.
There was no statistically signiﬁcant diﬀerence between two
groups(RR,0.39;95%CI,0.10to1.55; P = 0.18)(Figure 3).
Adverse Eﬀect. Four trials [10, 12, 13, 16]r e p o r t e da d v e r s e
events, while the other three did not mention it. No obvious4 Evidence-Based Complementary and Alternative Medicine
Table 2: Quality assessment of included randomized controlled trials.
Study ID Sequence generation Allocation
concealment
Incomplete
outcome data Blinding Other source
of bias
Selective outcome
reporting
Risk of
bias
Liang 2000 [15] Unclear Unclear No Unclear Unclear No Unclear
Tan et al. 2003
[10]
Table of random
number Unclear Yes Unclear Unclear No Unclear
Wu et al. 2007
[17] Unclear Unclear No Unclear Unclear No Unclear
Yan and Li 2010
[13] Unclear Unclear Yes Unclear Unclear Yes Unclear
Yang et al. 2003
[12] Unclear Unclear No Unclear Unclear No Unclear
Zeng and Feng
2003 [11] Unclear Unclear No Unclear Unclear No Unclear
Yu and Liao
1999 [16] Unclear Unclear Yes Unclear Unclear No Unclear
Study or subgroup
Liang S.H. 2000
Tan F. 2003
Wu X.W. 2007
Yan W.P. 2010
Yang W.X. 2003
Yu B.R. 1999
Zeng H. 2003
Total (95% CI)
Total events
Events
31
26
44
71
27
16
32
247
Total
40
33
46
75
30
20
34
278
Events
20
25
33
68
22
9
23
200
Total
40
32
42
75
28
20
30
267
Weight
3.6%
6.8%
15.4%
54.4%
8.6%
1.6%
9.6%
100.0%
IV, ﬁxed, 95% CI
1.55 [1.09, 2.20]
1.01 [0.78, 1.30]
1.22 [1.03, 1.44]
1.04 [0.95, 1.14]
1.15 [0.91, 1.44]
1.78 [1.04, 3.03]
1.23 [0.99, 1.52]
1.12 [1.04, 1.19]
IV, ﬁxed, 95% CI
0.5 0.7 1 1.5 2
Favours control Favours experimental
Qingkailing injection Control Risk ratio Risk satio
Heterogeneity: χ2 = 10.80, df = 6 (P = 0.09); I2 = 44%
Test for overall eﬀect: Z = 3.25 (P =0.001)
Figure 2: Forest plot of comparison: eﬀect rate.
adverse events occurred in three trials, and one trial [10]
reported adverse events described as eruption and dizziness;
however, eruption also appeared in control group. The
duration of treatment in all included studies was short (7
to 20 days). Outcomes were measured within 1 month after
stroke onset, without longer followup. Although few related
information about adverse eﬀects was recorded, potential or
long-time adverse eﬀects in the included trials could not be
excluded (Table 1).
3.3.2. Secondary Outcomes
MESSS Scoring. Three trials (272 patients) [11–13]r e p o r t e d
detailed neurological deﬁcit scoring (MESSS). The scoring
performed no signiﬁcant diﬀerence between two groups
before treatment, and meta-analysis of data on MESSS
scoring at the end of duration of treatment showed that
QKL injection plus conventional treatment had more beneﬁt
comparedwithconventionaltreatmentalone(WMD: −3.49;
95% CI, −4.70 to −2.28; P<0.01) (Figure 4).
Infarction Volume. One trial [12] assessed infarction volume
of CT, before treatment and at the end of 21 days of
treatment, respectively, using the formula of quantitative
estimation on hematoma. The baseline of infarction volume
had no signiﬁcant diﬀerence between two groups and
the infarction volume of QKL group at endpoint reduced
signiﬁcantly more than control (WMD, −1.85; 95% CI,
−3.40 to −0.30; P = 0.02).
Inﬂammation Factor. Two trials [10, 14]p r o v i d e dd a t ao f
inﬂammation factors in blood serum. They both reported
TNF-α and IL-6, so we make meta-analysis of them. At
the end of treatment, results showed there was signiﬁcant
diﬀerence between QKL treatment and routine treatment
groups for TNF-α level (WMD −5.56; 95% CI, −9.23 to
−1.90;P<0.01),butnostatisticsigniﬁcanceforIL-6(WMD
−22.61; 95% CI, −53.91 to 8.68; P = 0.16) (Figure 5).
Revival of Coma. Yang et al. [12] reported the eﬀect of
QKL injection in reviving coma induced by stroke. In QKLEvidence-Based Complementary and Alternative Medicine 5
Tan F. 2003
Yu B.R. 1999
Total (95% CI)
Total events
2
1
3
33
20
53
2
7
9
32
20
52
52.6%
47.4%
100.0%
0.97 [0.15, 6.47]
0.14 [0.02, 1.06]
0.39 [0.10, 1.55]
0.01 0.1 1 10 100
Study or subgroup Events Total Events Total weight IV, ﬁxed, 95% CI IV, ﬁxed, 95% CI
Qingkailing injection Control Risk ratio Risk ratio
Favours control Favours experimental
Heterogeneity: χ2 = 1.85, df = 1 (P = 0.17); I2 = 46%
Test for overall eﬀect: Z = 1.33 (P =0.18)
Figure 3: Forest plot of comparison: death.
Study or subgroup
Yan W.P. 2010
Yang W.X. 2003
Zeng H. 2003
Total (95% CI)
Mean
12.99
7.46
5.16
SD
4.12
4.56
6.07
Total
75
30
34
139
Mean
15.9
12.46
9.2
SD
5.16
5.76
7.19
Total
75
28
30
133
weight
65.9%
20.4%
13.7%
100.0%
IV, ﬁxed, 95% CI IV, ﬁxed, 95% CI
0 2 4
Favours control Favours experimental
Qingkailing injection Control Mean difference Mean difference
Heterogeneity: χ2 = 1.90, df = 2 (P = 0.39); I2 = 0%
Test for overall eﬀect: Z = 5.64 (P<0.00001)
−4 −2
Figure 4: Forest plot of comparison: MESSS scoring.
injection treatment group, 11 coma cases out of 13 revived
within 7 days, while in control group that was only 4 out of
10 (RR, 2.12; 95% CI, 0.96 to 4.68; P = 0.06).
3.3.3.QualityofLife. Onlyonetrial[11]reportedroutinelife
status using scoring recommended at the Second and revised
at the Fourth National Cerebrovascular Diseases Conference
in China [18]. At the end of treatment, QKL treatment
signiﬁcantly improved routine living ability than control
group (WMD, −0.96; 95% CI, −1.84 to 0.08; P = 0.03).
3.4. Publication Bias. Although we conducted comprehen-
sive searches and tried to avoid bias, since all trials were pub-
lished in Chinese, we could not exclude potential publication
bias.
4. Discussion
This review of randomized trials showed the current evi-
dence in QKL injection for acute ischemia stroke. In many
years, Western medicine has made tremendous progress and
had become the dominating medical treatment worldwide.
However, it has been increasingly recognized that Western
medicine may sometimes fail to treat an illness, whereas
such illness is reportedly improved by the so-called com-
plementary medicine based on a diﬀerent theory [19, 20].
Traditional Chinese patent medicine (TCPM) for stroke is
very popular in China [1, 2, 17]. Currently, there are more
than 100 TCPM used for stroke and approved by the Chinese
StateFoodandDrugAdministration[17].QKLinjectionhas
been applied for more than 30 years. However, few relevant
articles on QKL injection for stroke have been published
in the English medical journals. One systemic review about
TCPM for ischemic stroke published in 2007 included only
2 trials of QKL injection [17]. One of them was included in
thisstudy,whiletheotherexcludedfornotmeetinginclusion
criteria.
The data from the 7 RCTs that were analyzed demon-
strated that, QKL injection plus conventional medication
maybemoreeﬀectivethanconventionalmedicationalonefor
acute ischemia stroke. With evaluating the improvement of
classiﬁcation of neurological function using MESSS scoring
(RR, 1.12; 95% CI, 1.04 to 1.19), the eﬀect rate of QKL
plusconventionalmedicinetreatmentgroupwas,onaverage,
14 percent more than control group using conventional
medicine alone. In consistency with it, meta-analysis of
detailed neurological deﬁcit scoring (MESSS) in three trails
also showed QKL group had more beneﬁt in improving neu-
rological function. These results were positively encouraging
and promising of combining QKL injection with conven-
tional treatment, which might be beneﬁcial to acute ischemic
stroke.
However, there were several limitations in this paper.
No multicenter, large sample and cooperative studies were
found and most of the existing trials were of small size,
yet no trials estimated the sample size. Although all tri-
als claimed randomization, most of them failed to provide
enough information to judge whether the randomization
procedures had been carried out properly. And inadequate
reporting of allocation concealment, blinding, intention to
treat analysis, and dropouts account in all the trials may
have created potential performance biases and detection
biases, as patients and researchers might have been aware of
the therapeutic interventions. So every trial had an unclear
risk of bias or a high risk of bias. Although we conducted
comprehensive searches and tried to avoid bias, since all6 Evidence-Based Complementary and Alternative Medicine
Tan F. 2003
Wu X.W. 2007
Total (95% CI)
9.08
5.8
2.27
1.7
33
46
79
16.52
9.5
2.16
2.8
32
42
74
49.8%
50.2%
100.0%
Study or subgroup Mean SD Total Mean SD Total weight IV, random, 95% CI IV, random, 95% CI
Qingkailing injection Control Mean difference Mean difference
05 1 0 −10 −5
Favours control Favours experimental
−7.44 [−8.52, −6.36]
−3.70 [−4.68, −2.72]
−5.56 [−9.23, −1.90]
Heterogeneity: τ2= 6.72; 
Test for overall eﬀect: Z = 2.97 (P =0.003)
χ2 = 25.37, df = 1 (P < 0.00001); I2 = 96%
Figure 5: Forest plot of comparison: TNF-α.
trials were published in Chinese, there remained the possible
existence of publication bias.
This paper showed a very low case fatality rate (12
deaths out of total 547 patients). There were several possible
explanations for the striking ﬁnding: truly low case fatality
rate for stroke in China; severe stroke patients were not sent
to hospitals; severe stroke cases were excluded by Chinese
stroke physicians in research studies; failure to report major
outcome events; or did not assess long-term outcome after
stroke onset. Those all resulted in bias. However, in the two
trials reporting death with limited sample size, there was a
tendency of reducing fatality rate in QKL injection group
without signiﬁcant diﬀerence.
For secondary outcomes, infarction volumes of CT and
inﬂammation factors in blood serum were reported in a few
trials. These results supported QKL injection’s eﬃciency, and
the later outcome was consistent with animal results about
the mechanism of QKL in ischemic model [6, 7]. Except
for one trial, most of trials did not mention quality of life,
which possibly was special advantage of TCM. We suggest
future trials for QKL to pay more attention to outcome
of life quality and comply with international standards in
the evaluation of life status. One trial reported eﬀect in
reviving stroke-induced coma and result showed more coma
cases in QKL group regained consciousness within one week;
however, with no statistic signiﬁcance because of limited
sample. It indicated that QKL may have excellent eﬀect
in restoring consciousness, which was called consciousness
restoringandobstructionclearing(Xingnaokaiqiao)inTCM
theory. Angongniuhuang pill was well known about its
excellent consciousness restoring and obstruction clearing
eﬀect, and QKL also was widely used to treat coma. So we
advise future RCTs to assess QKL eﬀect for subgroup of
severe stroke patients combined with coma.
Adverse eﬀects were reported by Tan et al. [10]a s
eruption and dizziness. No obvious adverse events occurred
in three trials, while other three trials did not report adverse
eﬀects. However, the concrete conclusion regarding safety
cannot be determined from this paper due to the limited
evidence provided by the eligible trials. Another paper about
the safety of QKL concluded that, although some cases of
adverse eﬀects for QKL were reported, QKL carries a low
risk of adverse drug reactions and adverse events, and some
adverseeventsthatdooccurmaybeascribedtoimproperuse
of the drug [21]. In order to proper assess the safety of QKL
injection, large-scale clinical trials with long-term followup
are required.
In conclusion, a deﬁnite conclusion on eﬃcacy and
adverse events associated with QKL injection cannot be
drawnfromthispaperbecauseoftheunclearmethodological
quality of these included trials. The general lack of reporting
of methodology in these trials publication was not consistent
with the CONSORT statement on the reporting of the results
of randomized trials (http://www.consort-statement.org/),
which is being highlighted in many journals around the
world. Future trials should overcome the limitations of
the trials presented in this paper; particularly, they should
assure adequate concealment of allocation and blinding of
outcome assessors and report both of fatality rate and eﬀect
rate as the primary outcomes at long-term followup, and
evaluate routine living ability using international standards.
If the positive eﬀects of QKL injection were conﬁrmed
by comprehensive clinical trials, it would lead to many
promising treatments for acute ischemic stroke and could
beneﬁt patients all over the world.
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